ClinicalTrials.gg
CompletedNCT03048747Updated Nov 2, 2020Results posted

A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH

A Phase 3 interventional study of Tolvaptan Oral Tablet in Syndrome of Inappropriate Antidiuretic Hormone Secretion, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 6 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-11-02.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Inappropriate ADH Syndrome · Otsuka Holdings Co., Ltd..

Started
2017
the only one that year
Phase 3
4 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd., this one is the only one that started in 2017, is one of 4 in phase 3, and was the 9th registered.

Inappropriate ADH Syndrome

41 studies on the registry are indexed under Inappropriate ADH Syndrome; 3 are open to participants now.

Browse Inappropriate ADH Syndrome studies →

Open to participants now

None of the 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd. is open now. The open studies under Inappropriate ADH Syndrome, anywhere →

Who these studies take

Of the 3 Inappropriate ADH Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

The objective of this study is to investigate the efficacy and safety of tolvaptan based on the change in serum sodium concentration following administration of tolvaptan oral tablets at 7.5 to 60 mg/day for up to 30 days in patients with hyponatremia in the SIADH.

03

Conditions studied

  • Syndrome of Inappropriate Antidiuretic Hormone Secretion
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a definite diagnosis of SIADH in reference to "Diagnostic and Treatment Manual of the Hypersecretion of Vasopressin (SIADH), Revised in 2011"
  • Subjects who have been on fluid restriction for at least 7 consecutive days at the time of and who are showing no improvement of hyponatremia at the time of the screening examination

Exclusion criteria

Exclusion Criteria:

  • Subjects who have transient hyponatremia induced by drug administration
  • Subjects who are unable to sense thirst or who have difficulty with fluid intake
  • Subjects with urinary tract obstruction
  • Subjects who have participated in any other clinical trial within 30 days prior to
  • Subjects with serum sodium concentration of \<120 mEq/L associated with neurologic impairment, including apathy, confusion, or seizures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Tolvaptan

    Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.

    Drug: Tolvaptan Oral Tablet

Interventions

  • Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration

    The percentage of subjects with normalized serum sodium concentration, defined as ≥135 mEq/L, on the day after final IMP administration will be calculated versus the number of subjects with serum sodium concentration of \<135 mEq/L at baseline on Day 1 of the treatment period.

    Time frame: Baseline, Day2, Day3, Day4, Day5, Day7, Day14, Day21, Day after final study medication

Secondary outcomes

  1. Change in Serum Sodium Concentration

    The mean and standard error of measured values for serum sodium concentration on the day of fixing the maintenance dose and on the day after final IMP administration were calculated. The day of fixing the maintenance dose: Day2, Day3, Day4, Day5, Day7, Day14, and Day21

    Time frame: Day2, Day3, Day4, Day5, Day7, Day14, Day21 and the day after final IMP administration

07

Results

Posted Nov 2, 2020

Participant flow

This trial was conducted in 16 participants from 31 trial sites in Japan.

Participant flow — Overall Study
MilestoneTolvaptan
Started16
Completed11
Not completed5
Withdrew: Adverse event2
Withdrew: Participant met withdrawal criteria2
Withdrew: Physician decision1

Outcome measures

PrimaryPercentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration

The percentage of subjects with normalized serum sodium concentration, defined as ≥135 mEq/L, on the day after final IMP administration will be calculated versus the number of subjects with serum sodium concentration of \<135 mEq/L at baseline on Day 1 of the treatment period.

Time frame:
Baseline, Day2, Day3, Day4, Day5, Day7, Day14, Day21, Day after final study medication
Reported as:
Number · percentage of participants
Percentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration
percentage of participantsTolvaptan
Day243.8
Day380
Day480
Day585.7
Day792.9
Day1483.3
Day2181.8
Day after final study medication81.3
SecondaryChange in Serum Sodium Concentration

The mean and standard error of measured values for serum sodium concentration on the day of fixing the maintenance dose and on the day after final IMP administration were calculated. The day of fixing the maintenance dose: Day2, Day3, Day4, Day5, Day7, Day14, and Day21

Time frame:
Day2, Day3, Day4, Day5, Day7, Day14, Day21 and the day after final IMP administration
Reported as:
Mean · mEq/L
Change in Serum Sodium Concentration
mEq/LTolvaptan
Day26.9 ± 2.6
Day38.1 ± 3.8
Day48.5 ± 4.6
Day58.8 ± 4.4
Day710.0 ± 4.5
Day1410.8 ± 3.7
Day2110.4 ± 6.0
Day after final study medication11.0 ± 4.3

Adverse events

Collected over Adverse events were monitored from signing of the informed consent form until follow-up, up to 7 weeks on average.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan1/16 (6.3%)5/16 (31.3%)15/16 (93.8%)
Most frequent serious events
Most frequent serious events
EventTolvaptan
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/16
Supraventricular extrasystolesCardiac disorders1/16
Ventricular extrasystolesCardiac disorders1/16
BacteraemiaInfections and infestations1/16
Back painMusculoskeletal and connective tissue disorders1/16
Loss of consciousnessNervous system disorders1/16
Paralysis of recurrent laryngeal nerveNervous system disorders1/16
Circulatory collapseVascular disorders1/16
HaemorrhageVascular disorders1/16
Most frequent other events
Showing 10 of 56
Most frequent other events
EventTolvaptan
ThirstGeneral disorders3/16
Decreased appetiteMetabolism and nutrition disorders3/16
NeutropeniaBlood and lymphatic system disorders2/16
ConstipationGastrointestinal disorders2/16
NauseaGastrointestinal disorders2/16
VomitingGastrointestinal disorders2/16
PyrexiaGeneral disorders2/16
GingivitisInfections and infestations2/16
FallInjury, poisoning and procedural complications2/16
Blood creatinine increasedInvestigations2/16

Baseline characteristics

Safety analysis set, which included in patients who received ≥1 dose of the study medication.

Age, Categorical
Age, Categorical(Participants)Tolvaptan
<=18 years0
Between 18 and 65 years1
>=65 years15
Age, Continuous
Age, Continuous(years)Tolvaptan
Mean71.9 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)Tolvaptan
Female3
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tolvaptan
Japanese16
Region of Enrollment
Region of Enrollment(participants)Tolvaptan
Japan16
08

Study locations

6 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Sikoku Region, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Supporting Materials: Study Protocol and Statistical Analysis Plan (SAP) Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data. Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available aftermarketing approval in global markets, or beginning1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and Ranalytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Mar 2019, 24 months.

Results were first posted in Nov 2020, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2017
First posted
Feb 9, 2017
StartActual
Mar 2, 2017
Primary completionActual
Mar 19, 2019
CompletionActual
Mar 19, 2019
Results first posted
Nov 2, 2020
Last update
Nov 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03048747
Responsible party
Sponsor
First posted
Feb 9, 2017
Start date
Mar 2, 2017
Primary completion
Mar 19, 2019
Completion
Mar 19, 2019
Results posted
Nov 2, 2020
Last update
Nov 2, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion